The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Predicting risk of fracture in MGUS patients
Dr Jad Sfeir MD, of the Mayo Clinic College of Medicine, Rochester, MN, discusses the significance of monoclonal gammopathy of undetermined significance (MGUS), and why improved clinical availability of measures of bone micro-architecture would be invaluable in the better estimation of fracture risk. Discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
